Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience.
Forty-two patients with recurrent respiratory papillomatosis (RRP) were accepted into a multicenter prospective study in 1983 to 1990, treated with alfa-IFN 3 MU/m 2 3 times a week and then followed-up until August 1, 2003. All the patients who had disease progression with pulmonary spread were characterized by insufficient response to IFN-therapy and detection of HPV type 11. Five patients (4/5 smokers) presented malignant transformation in lungs or nasopharynx (mean RRP duration was 27.2 +/- 8 years from RRP onset and 14.6 +/- 6.3 years from pulmonary spread until malignant transformation) with persistent RRP in larynx. The results of long-term follow-up in RRP patients with HPV 11 underline the necessity of reanalyzing the current therapy.
Gerein
Valentin
V
Department of Pediatric Pathology, Institute of Pathology, University of Mainz, Germany. v.gerein@web.de
Rastorguev
Eugen
E
Gerein
Johann
J
Draf
Wolfgang
W
Schirren
Joachim
J
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D002471:Cell Transformation, Neoplastic; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D010212:Papilloma / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D011446:Prospective Studies; D013997:Time Factors; D017211:Treatment Failure